Volume 85, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



To assess immunity after yellow fever (YF) 17D live-attenuated vaccination, we measured the antibody levels before vaccination and at 21 days and 8 months after vaccination in YF-naïve travelers. Thirty subjects were enrolled in the study, with 100% providing sera at 21 days and 86.6% providing sera at 8 months. All subjects seroconverted by day 21, and the geometric mean titers of the anti-YF antibodies decreased between day 21 and month 8 from 6,451 to 1,246. This study corroborates the high rates of seroconversion achieved by the live-attenuated YF vaccine.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Tourism Organization, 2010. UNWTO Tourism Highlights. Available at: www.unwto.org/facts/menu.html. Accessed March 28, 2011.
  2. Monath TP, Cetron MS, , 2002. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34: 13691378.[Crossref]
  3. Monath TP, Fowler E, Johnson C, Balser J, Morin M, Sisti M, Trent D, , 2011. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 364: 13261333.[Crossref]
  4. Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL, , 2006. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24: 28432849.[Crossref]
  5. Wisseman CL, Jr Sweet BH, Kitaoka M, Tamiya T, , 1962. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. Am J Trop Med Hyg 11: 550561.
  6. Monath TP, , 1971. Neutralizing antibody responses in the major immunoglobulin classes to YF 17D vaccination of humans. Am J Epidemiol 93: 122129.[Crossref]
  7. Spector S, Tauraso NM, , 1968. Yellow fever virus. I. Development and evaluation of a plaque neutralization test. Appl Microbiol 16: 17701775.
  8. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, , 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533541.
  9. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C, , 1999. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Hyg 60: 10451050.
  10. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, , 1981. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895900.
  11. Kayser M, Klein H, Paasch I, Pilaski J, Blenk H, Heeg K, , 1985. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. J Med Virol 17: 3545.[Crossref]
  12. Rosenzweig EC, Babione RW, Wisseman CL, Jr, 1963. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 12: 230235.
  13. Monath TP, Lee VH, Wilson DC, Fagbami A, Tomori O, , 1974. Arbovirus studies in Nupeko Forest, a possible site of endemic yellow fever transmission in Nigeria. I. Serosurvey of humans and non-human primates. Trans R Soc Trop Med Hyg 68: 3038.[Crossref]
  14. Vinner L, Domingo C, Ostby AC, Rosenberg K, Fomsgaard A, , 2011. Cases of travel-acquired dengue fever in Denmark 2001–2009. Clin Microbiol Infect Apr 5. doi: 10.1111/j.1469-0691.2011.03543.x. [Epub ahead of print].

Data & Media loading...

  • Received : 10 Jun 2011
  • Accepted : 17 Jul 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error